Pfizer Inc. reports mixed late-stage results for two phase 3b Lyrica studies

Fibromyalgia study shows reduction in pain; diabetic peripheral neuropathy misses the mark

| 1 min read

Listen with Speechify

0:00

1:00

Pfizer Inc. announced top-line results from two phase IIIb, placebo-controlled studies with Lyrica (pregabalin) capsules CV in patients with fibromyalgia (FM) and painful diabetic peripheral neuropathy (DPN), respectively. The fibromyalgia study, A0081275 met its primary endpoint, showing a reduction in pain associated with fibromyalgia in patients who were treated concurrently with antidepressant therapy for comorbid depression. Separately, the painful DPN study, A0081269 did not meet its co-primary endpoints by sufficiently reducing DPN pain and DPN pain on walking compared to placebo.

About the Author

Lloyd Dunlap
This person does not yet have a bio.

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Fluorescent-style illustration of spherical embryonic stem cells clustered together against a dark background.

Advancing predictive in vitro models

Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.

Webinars